**Author details**

#### Kosaku Nitta

Address all correspondence to: knitta@kc.twmu.ac.jp

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan

### **References**


[11] Elliott RJ, McGrath LT. Calcification of the human thoracic aorta during age. Calcif Tissue Int 1994; 54: 268–73.

**Author details**

12 Updates in Hemodialysis

Address all correspondence to: knitta@kc.twmu.ac.jp

Am Soc Nephrol 2008; 19: 213–6.

ney Int 2007; 71: 802–7.

ney Dis 2004; 44: 680–8.

2004; 27: 47–52.

63: 793–808.

Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan

[1] Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone

[2] Goldsmith D, Covic A, Sambrook P, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77:

[3] Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J

[4] Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial 2007; 20:

[5] Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1489–96.

[6] Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kid‐

[7] Nitta K, Akiba T, Uchida K, et al. Left ventricular hypertrophy is associated with ar‐ terial stiffness and vascular calcification in hemodialysis patients. Hypertens Res

[8] Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kid‐

[9] Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification

[10] Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. (2003) Reverse epidemiolo‐ gy of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;

in patients on hemodialysis. Nephrol Dial Transplant 2010; 26: 1327–39.

disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14; 3–12.

Kosaku Nitta

**References**

37–43.

103–9.


[38] Shimada T, Hasegawa H, Yamazaki Y, et al. FGF23 is a potent regulator of the vita‐ min D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429–35.

[24] Kanbay M, Goldsmith D, Akcay A, Covic A. Phosphate: the silent stealthy cardiore‐ nal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif

[25] Kestenbaum B, Sampson JN, Rudser KD, et al. Patterson, D. J., Seliger, S. L., Young, B., Sherrard, D. J. and Andress, D. L. (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520–8.

[26] Yang H, Curinga G, Giachelli, C. Elevated extracellular calcium levels induce smooth

[27] Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calci‐ um and phosphate concentrations: a potential mechanism for accelerated vascular

[28] Jono S, McKee M, Murry C, et al. Phosphate regulation of vascular smooth muscle

[29] El-Abbadi MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial cal‐ cification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and

[30] Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney dis‐

[31] Levin A, Bakris G, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study

[33] Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1128–

[34] Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest 2002; 110: 229–38.

[35] Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of sec‐

[36] Mathew S, Lund R, Chaudhary L, Geurs T, Hruska K. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509–19.

[37] Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J

ondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370–7.

muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293–9.

calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857–67.

to evaluate early kidney disease. Kidney Int 2007; 71: 31–8.

[32] Holick M. Vitamin D deficiency. N Engl J Med 2007; 357: 266–81.

cell calcification. Circ Res 2000; 87: E10–17.

osteopontin. Kidney Int 2009; 75: 1297–307.

ease. Am J Kidney Dis 2003; 42: S1–201.

Clin Invest 2004; 113: 561–8.

35.

2009; 27: 220–30.

14 Updates in Hemodialysis


study comparing EBCT-generated coronary artery calcium scores and coronary an‐ giography. Nephrol Dial Transplant 2004; 19: 2307–12.

[66] Moe SN, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, Meyer CA. Assess‐ ment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Trans‐ plant 2003; 18: 1152–1158

[52] Price P, Williamson M. Primary structure of bovine matrix Gla protein, a new vita‐

[53] Cancela L, Hsieh CL, Francke U, Price PA, (1990) Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol

[54] Luo G, Ducy P, McKee M, et al. Spontaneous calcification of arteries and cartilage in

[55] Bostrom K, Tsao D, Shen S, Wang Y, Demer L. Matrix GLA protein modulates differ‐ entiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem

[56] Parker B, Ix J, Cranenburg E, Vermeer C, Whooley M, Schurgers L. (2009) Associa‐ tion of kidney function and uncarboxylated matrix Gla protein: data from the Heart

[57] Collin-osdoby P. Regulation of vascular calcification by osteoclast regulatory factors

[58] Morena M, Dupuy AM, Jaussent I, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney dis‐

[59] Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vas‐ cular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886–

[60] Bennet BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates ad‐ vanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Ar‐

[61] Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. (2003) In‐ creased osteoprotegerin serum levels in men with coronary artery disease. J Clin En‐

[62] Salazar H, Raggi P. Usefulness of electron-beam computed tomography. Am J Cardi‐

[63] Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. (2004) Deter‐ minants of progressive vascular calcification in haemodialysis patients. Nephrol Dial

[64] Sharples E, Pereira D, Summers S, et al. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery an‐

[65] Haydar A, Hujairi N, Covic A, Pereira D, Rubens M, Goldsmith D. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a

giography in dialysis patients. Am J Kidney Dis 2004; 43: 313–9.

min K-dependent bone protein. J Biol Chem 1985; 260: 14971–5.

mice lacking matrix GLA protein. Nature 1997; 386: 78–81.

and Soul Study. Nephrol Dial Transplant 2009; 24: 2095–101.

RANKL and osteoprotegerin. Circ Res 2004; 95: 1046–57.

ease patients. Nephrol Dial Transplant 2009; 24: 3389–97.

terioscler Thromb Vasc Biol 2006; 26: 2117–24.

docrinol Metab 2003; 88: 1024–8.

Transplant 2004; 19: 1489–96.

ol 2002; 89: 17B-22B.

Chem 1990; 265: 15040–8.

16 Updates in Hemodialysis

2001; 276: 14044–52.

9.

